Susan E Cottrell

20030148290, Aug 7, 2003

Feb 6, 2002

10/068553

Susan Cottrell - Seattle WA, US

C12Q001/68
C12P019/34

435/006000, 435/091200

Described is a method for methylation detection in a DNA sample. An isolated genomic DNA sample is treated in a manner capable of distinguishing methylated from unmethylated cytosine bases. The pretreated DNA is amplified using at least one oligonucleotide primer, a polymerase and a set of nucleotides of which at least one is labeled with a first type of label. A sequence-specific oligonucleotide probe, marked with a second type of label, hybridizes to the amplification product and a FRET reaction occurs if a labeled oligonucleotide is present in close proximity in the amplification product. The method determines the level of methylation of a sample by measuring the extent of fluorescence resonance energy transfer (FRET) between the donor and acceptor fluorophore.

20040029121, Feb 12, 2004

Aug 8, 2002

10/215890

Susan Cottrell - Seattle WA, US
Suzanne Mooney - Seattle WA, US

C12Q001/68
C07H021/04

435/006000, 536/024300

The disclosed invention provides methods and sequences for the analysis of methylation patterns within a novel 5′ upstream CpG island of the calcitonin gene.

20040029128, Feb 12, 2004

Oct 25, 2002

10/281076

Susan Cottrell - Seattle WA, US
Suzanne Mooney - Seattle WA, US

Epigenomics, Inc.

C12Q001/68
C07H021/04

435/006000, 536/024300

The disclosed invention provides methods and sequences for the analysis of methylation patterns within a novel 5′ upstream CpG island of the calcitonin gene. Particular embodiments provide methylation-altered DNA sequences as novel diagnostic, prognostic and therapeutic markers for cancer.

20040146868, Jul 29, 2004

Jan 24, 2003

10/350763

Susan Cottrell - Seattle WA, US
Andrew Sledziewski - Shoreline WA, US

Epigenomics AG - Berlin

C12Q001/68

435/006000

The present invention provides for molecular GSTP1 markers that have novel utility for the analysis of methylation patterns within the promoter region and exons 1 and 2 of the GSTP1 gene, and are further useful in methods to effectively distinguish among benign hyperplasia of the prostate and different grades of prostate cancer. Additionally, the subject molecular GSTP1 markers have novel utility for the precise localization of the zone of origin to provide sensitive, accurate and non-invasive methods for the diagnosis and/or prognosis of prostate cell proliferative disorders. The present invention has novel utility for the detection and differentiation of a cell proliferative disorder of the peripheral zone of the prostate.

20050003463, Jan 6, 2005

Feb 13, 2003

10/482823

Peter Adorjan - Berlin, DE
Matthias Burger - Berlin, DE
Sabine Maier - Berlin, DE
Ralf Lesche - Berlin, DE
Susan Cottrell - Seattle WA, US
Theo De Vos - Seattle WA, US

C12Q001/68
G01N033/574

435007230

The invention provides methods and nucleic acids for detecting, differentiating or distinguishing between colon cell proliferative disorders as well as therapy thereof by analysis of the gene EYA4 and its promoter and regulatory sequences. The invention further provides novel nucleic acid sequences useful for the cell proliferative disorder specific analysis of said gene as well as methods, assays and kits thereof.

20060088866, Apr 27, 2006

Oct 17, 2005

11/252135

Susan Cottrell - Seattle WA, US

C12Q 1/68
C12P 19/34

435006000, 435091200

Described is a method for methylation detection in a DNA sample. An isolated genomic DNA sample is treated in a manner capable of distinguishing methylated from unmethylated cytosine bases. The pretreated DNA is amplified using at least one oligonucleotide primer, a polymerase and a set of nucleotides of which at least one is labeled with a first type of label. A sequence-specific oligonucleotide probe, marked with a second type of label, hybridizes to the amplification product and a FRET reaction occurs if a labeled oligonucleotide is present in close proximity in the amplification product. The method determines the level of methylation of a sample by measuring the extent of fluorescence resonance energy transfer (FRET) between the donor and acceptor fluorophore.

20060234224, Oct 19, 2006

Feb 27, 2003

10/506089

Peter Adorjan - Berlin, DE
Matthias Burger - Berlin, DE
Sabine Maier - Berlin, DE
Ralf Lesche - Berlin, DE
Susan Cottrell - Seattle WA, US
Suzanne Mooney - Seattle WA, US

C12Q 1/68
C07H 21/04
C07K 14/47

435006000, 530350000, 536024300

The invention provides methods and nucleic acids for detecting, differentiating or distinguishing between colon cell proliferative disorders by analysis of one or more of the genes Versican, TPEF, H-Cadherin, Calcitonin, and EYA4. The invention further provides novel nucleic acid sequences useful for the cell proliferative disorder specific analysis of said genes as well as methods, assays and kits thereof.

20080286761, Nov 20, 2008

Dec 1, 2004

10/581224

J. Kevin Day - Syracuse UT, US
Susan Cottrell - Seattle WA, US
Juergen Distler - Berlin, DE
Andrew Morotti - Seattle WA, US
Su Yamamura - Bellevue WA, US
Sharon Dekker - Beaverton OR, US
Yreka Ocampo - San Marcos CA, US
Theo Devos - Seattle WA, US

Epigenomics AG - Berlin

C12Q 1/68
C07H 21/00

435 6, 536 235

The following application provides methods and nucleic acids for the detection of and/or differentiation between prostate cell proliferative disorders. This is achieved by the analysis of the expression status of a panel of genes, or subsets thereof.